Entire Patients (n = 86) | Hazard Ratio | 95% CI | P |
---|---|---|---|
NEL type | |||
 Tumor-dominant | 2.03 | 1.24–3.32 | .005 |
 Edema-dominant | 1 |  |  |
CE evolution pattern | |||
 Enlarging residual CE (pattern 4) | 4.33 | 2.02–9.28 | <.001 |
 New measurable CE (pattern 3) | 3.00 | 1.63–5.54 | <.001 |
 Stable or responding residual CE (pattern 2) | 2.44 | 0.80–7.28 | .117 |
 New non-measurable CE (pattern 1) | 1 |  |  |
Patients with edema-dominant NEL (n = 41) | |||
 Enlarging residual CE (pattern 4) | 6.92 | 1.71–27.93 | .007 |
 New measurable CE (pattern 3) | 5.36 | 2.10–13.66 | <.001 |
 Stable or responding residual CE (pattern 2) | 2.63 | 0.31–21.98 | .372 |
 New non-measurable CE (pattern 1) | 1 |  |  |